ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. ITB-MED is wholly committed to advancing and exploring the potential of TCD601, with a particular focus on its applications in transplantation and autoimmunity. The efforts extend to comprehensive worldwide clinical trials. ITB-MED is actively investigating further preclinical therapies to expand the reach of its novel immune-modulating approaches.
